Inhibition of insulin receptors by vanadate and ouabain.
Insulin binding studies were performed, using cells from 5 non-obese, non-diabetic subjects, on four separate days: 2 were paired control studies to demonstrate precision, and 2 other sets were binding studies in which one incubation solution was a control and the other contained either vanadate, (10(-4) M) or ouabain (10(-4) M). For both substances tracer binding of 125I insulin was reduced significantly, 27% by vanadate and 30% by ouabain. Furthermore, at all points on the binding curve these substances inhibited binding by 18-98%, in a pattern consistent with reduced receptor number. The concentrations of vanadate or ouabain which we used did not change cell volume or inhibit trypan blue dye exclusion, as an index of cell viability. Because vanadate and ouabain inhibit Na+K+ATPase and have largely dissimilar effects on a variety of cell systems, our observations may reflect specific involvement of Na+K+ATPase in binding or closely related processes.
Levin
S R
SR
Diabetes Research Laboratory, Wadsworth VA Medical Center, Los Angeles, California 90073.
Aftergood
D E
DE
Fanous
E
E
Whitson
R H
RH
D000328:Adult; D002462:Cell Membrane / Q000378:metabolism; D005260:Female; D006801:Humans; D007328:Insulin / Q000378:metabolism; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism*; D010042:Ouabain / Q000494:pharmacology*; D011972:Receptor, Insulin / Q000187:drug effects / Q000378:metabolism*; D014638:Vanadates / Q000494:pharmacology*
D007328:Insulin; D014638:Vanadates; D010042:Ouabain; D011972:Receptor, Insulin